MAAT PHARMA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.04 EUR | +0.50% |
|
+1.77% | +15.19% |
| May. 08 | Mickey Mouse on Wall Street |  |
| Apr. 15 | MaaT Pharma: positive data in graft-versus-host disease | CF |
| Sales 2024 * | 4M 4.34M | Sales 2025 * | 4.4M 4.78M | Capitalization | 111M 121M |
|---|---|---|---|---|---|
| Net income 2024 * | -29M -31.48M | Net income 2025 * | -29M -31.48M | EV / Sales 2024 * | 25.6 x |
| Net cash position 2024 * | 8.6M 9.33M | Net cash position 2025 * | 7.9M 8.57M | EV / Sales 2025 * | 23.5 x |
| P/E ratio 2024 * |
-3.43
x | P/E ratio 2025 * |
-3.35
x | Employees | 56 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on MaaT Pharma
More press releases
| 1 day | +0.50% | ||
| 1 week | +1.77% | ||
| Current month | -13.55% | ||
| 1 month | -14.10% | ||
| 3 months | +1.26% | ||
| 6 months | +16.52% | ||
| Current year | +15.19% |
1 week
7.84
8.10
1 month
7.849.58
Current year
6.409.90
1 year
4.509.90
3 years
4.5014.40
5 years
4.5014.40
10 years
4.5014.40
| Managers | Title | Age | Since |
|---|---|---|---|
Hervé Affagard
FOU | Founder | - | 13-12-31 |
Siân Crouzet
DFI | Director of Finance/CFO | - | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 13-12-31 | |
Claude Bertrand
BRD | Director/Board Member | 61 | 20-07-15 |
Muriel Prudent
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 8.04 | +0.50% | 11 |
| 24-05-28 | 8 | 0.00% | 1,529 |
| 24-05-27 | 8 | 0.00% | 314 |
| 24-05-24 | 8 | 0.00% | 1,674 |
| 24-05-23 | 8 | +1.27% | 267 |
Real-time Euronext Paris, May 29, 2024 at 03:15 am EDT
More quotes
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.
The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Calendar
2024-06-10
- Portzamparc Mid & Small Caps Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8
EUR
Average target price
14.6
EUR
Spread / Average Target
+82.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.19% | 121M | |
| +9.83% | 115B | |
| +10.80% | 105B | |
| -10.84% | 22.71B | |
| -0.44% | 21.83B | |
| -11.07% | 18.18B | |
| -41.92% | 16.52B | |
| -15.11% | 16.01B | |
| +6.62% | 14.14B | |
| +17.53% | 10.71B |
- Stock Market
- Equities
- MAAT Stock
